Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

EU begins real-time review of Sanofi-GSK COVID-19 vaccine

07/20/2021 | 01:13pm EDT
FILE PHOTO: The word

(Reuters) - Europe's drug regulator said on Tuesday it had started a real-time review of the COVID-19 vaccine developed by French drugmaker Sanofi and Britain's GlaxoSmithKline, the fifth shot currently under such a review.

The decision to start the "rolling review" of the vaccine, Vidprevtyn, was based on preliminary results from lab studies and early stage clinical trials in adults, the European Medicines Agency (EMA) said https://www.ema.europa.eu/en/news/ema-starts-rolling-review-covid-19-vaccine-vidprevtyn.

Late-stage global trials for the protein-based coronavirus vaccine candidate began in May.

Sanofi and GSK hope to get approvals by the end of 2021 after early-stage results showed the vaccine produces a robust immune response.

"EMA will assess the compliance of Vidprevtyn with the usual EU standards for effectiveness, safety and quality," the regulator said, without giving details on data it had received so far and an expected timeline for approval.

EMA's rolling reviews are aimed at speeding up the approval process by allowing researchers to submit findings in real time before final trial data is available.

Sanofi said other rolling reviews of its vaccine were also about to start in Britain, Canada and Singapore, as well as with the World Health Organization.

Vidprevtyn uses the same technology as one of Sanofi's seasonal influenza vaccines. It will be coupled with an adjuvant, a substance that acts as a booster to the shot, made by GSK.

Other COVID-19 vaccine candidates in EU's rolling review are those from CureVac, Novavax, Sinovac and Russia's Sputnik V.

(Reporting by Pushkala Aripaka in Bengaluru, additional reporting by Matthias Blamont in Paris; Editing by Giles Elgood)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
CUREVAC N.V. 0.00% 55.11 Delayed Quote.-32.02%
GLAXOSMITHKLINE PLC -0.49% 1388.2 Delayed Quote.3.44%
MSCI SINGAPORE (GDTR) 0.30% 6552.134 Real-time Quote.12.58%
NOVAVAX, INC. 0.11% 237.54 Delayed Quote.113.02%
SANOFI -0.15% 81.55 Real-time Quote.3.62%
Latest news "Economy & Forex"
05:58pEXCLUSIVE : U.S. opens probe into 30 million vehicles over air bag inflators
RE
05:20pU.S. TREASURY'S YELLEN : Debt default would 'permanently' weaken America
RE
02:10pU.s. cdc says 181,382,976 individuals have been fully vaccinated against covid-19 as of sept 19 versus 181,035,022 individuals as of sept 18
RE
02:10pU.s. cdc says 2.16 mln people received an additional covid-19 vaccine dose since august 13, 2021
RE
02:09pU.s. cdc says administered 385,586,012 doses of covid-19 vaccine as of sept 19 vs 384,911,290 doses administered as of sept 18
RE
02:09pU.s. cdc says 211,776,515 individuals have received at least one dose of covid-19 vaccine as of sept 19 versus 211,489,242 individuals as of sept 18
RE
02:08pU.s. cdc says delivered 466,561,785 doses of covid-19 vaccine as of sept 19 versus 466,569,635 doses delivered as of sept 18
RE
01:59pDEUTSCHE LUFTHANSA : Lufthansa launches $2.5 billion capital increase to repay state bailout
RE
01:42pWorld leaders return to U.N. with focus on pandemic, climate
RE
01:32pNigeria brings in custody rules to guard $9.7 billion funds industry
RE
Latest news "Economy & Forex"